Allergan Comes To Q3 Call With Deal News, But Nothing On Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan announced a licensing deal with Mimetogen to commercialize a TrkA agonist for the treatment of dry eye disease, coinciding with its third quarter earnings call and R&D day, but avoided discussion of the elephant in the room.
You may also be interested in...
Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.